Browsing Tag
GSK plc
25 posts
GSK specialty medicines sales rise 15% as £328m restructuring charge weakens reported profit
GSK reported £8.89 billion in third-quarter sales as specialty medicines expanded strongly across HIV, respiratory diseases and oncology. However, vaccines remained weak and a £328 million restructuring charge contributed to lower statutory earnings, while management maintained its 2026 and 2031 growth targets.
What does GSK’s Belgium job plan reveal about its £1.9bn cost reset?
GSK is preparing a major workforce reduction across three Belgian locations as Chief Executive Officer Luke Miels redirects spending toward late-stage medicines, vaccines and a leaner cost structure.
GSK commits more than $800m to Pennsylvania hub and 300 new jobs
GSK plc is committing more than $800 million to expand its Upper Merion, Pennsylvania operations into an integrated biologics manufacturing and research hub, creating more than 300 jobs over five years while retaining about 4,500 existing positions across the state. The investment follows another $800 million Pennsylvania project announced in 2024 and gives GSK a larger United States manufacturing footprint as its specialty medicines pipeline expands.
GSK bets up to $1.3bn on HUTCHMED’s preclinical KRAS-EGFR cancer therapy
GSK will pay HUTCHMED $110 million upfront and up to $1.185 billion in additional milestones for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR conjugate expected to enter human trials later in 2026.
GSK licenses HUTCHMED’s HMPL-A830 cancer therapy in deal worth up to $1.295bn
GSK plc has licensed HUTCHMED’s experimental KRAS-EGFR cancer therapy HMPL-A830 for up to $1.295 billion, giving the Chinese biotech a $110 million upfront payment before the drug enters its first human trial.
Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing
Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.
GSK Q2 2026 core operating profit rises 7% on specialty medicines strength
GSK Q2 core operating profit rose 7% to £2.8bn, but a £1.3bn camlipixant hit and 2028-2030 dolutegravir cliff frame the £40bn 2031 sales delivery test.
Sino Biopharmaceutical signs $1.9bn AstraZeneca deal and expands GSK alliance
Sino Biopharmaceutical signs a $1.9 billion AstraZeneca deal and expands GSK China respiratory rights. Read how 1177.HK could reshape growth.
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.
GSK Nuvalent acquisition puts $GSK in focus as $10.6bn oncology bet reshapes lung cancer pipeline
GSK is buying Nuvalent for USD 10.6bn to expand in lung cancer. Find out what the $GSK oncology deal means for investors.